WO2002004516A3 - Verwendungen des hitzeschockproteins gp96 - Google Patents

Verwendungen des hitzeschockproteins gp96 Download PDF

Info

Publication number
WO2002004516A3
WO2002004516A3 PCT/EP2001/007864 EP0107864W WO0204516A3 WO 2002004516 A3 WO2002004516 A3 WO 2002004516A3 EP 0107864 W EP0107864 W EP 0107864W WO 0204516 A3 WO0204516 A3 WO 0204516A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
heat shock
shock protein
apcs
antigens
Prior art date
Application number
PCT/EP2001/007864
Other languages
English (en)
French (fr)
Other versions
WO2002004516A2 (de
Inventor
Harpreet Singh-Jasuja
Hansjoerg Schild
Original Assignee
Harpreet Singh-Jasuja
Hansjoerg Schild
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harpreet Singh-Jasuja, Hansjoerg Schild filed Critical Harpreet Singh-Jasuja
Priority to AU2001285814A priority Critical patent/AU2001285814A1/en
Priority to CA002415434A priority patent/CA2415434A1/en
Priority to EP01965092A priority patent/EP1299113A2/de
Publication of WO2002004516A2 publication Critical patent/WO2002004516A2/de
Publication of WO2002004516A3 publication Critical patent/WO2002004516A3/de
Priority to US10/338,115 priority patent/US20030175249A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von gp96-Molekülen, die keine interessierenden Antigene tragen, zum Markieren und/oder Aktivieren von Antigen-präsentierenden Zellen (APCs), wie z.B. dendritische Zellen, Monocyten, Makrophagen, B-Zellen und peritoneale Exsudatzellen. Diese APCs können dann nach der Aktivierung mit Antigenen beladen werden und zur Induzierung einer Immunantwort oder im Rahmen einer Tumortherapie eingesetzt werden.
PCT/EP2001/007864 2000-07-10 2001-07-09 Verwendungen des hitzeschockproteins gp96 WO2002004516A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001285814A AU2001285814A1 (en) 2000-07-10 2001-07-09 Use of the heat shock protein gp96
CA002415434A CA2415434A1 (en) 2000-07-10 2001-07-09 Use of the heat shock protein gp96
EP01965092A EP1299113A2 (de) 2000-07-10 2001-07-09 Verwendungen des hitzeschockproteins gp96
US10/338,115 US20030175249A1 (en) 2000-07-10 2003-01-07 Uses of the heat shock protein gp96

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033245A DE10033245A1 (de) 2000-07-10 2000-07-10 Verwendungen des Hitzeschockproteins gp96
DE10033245.5 2000-07-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/338,115 Continuation US20030175249A1 (en) 2000-07-10 2003-01-07 Uses of the heat shock protein gp96

Publications (2)

Publication Number Publication Date
WO2002004516A2 WO2002004516A2 (de) 2002-01-17
WO2002004516A3 true WO2002004516A3 (de) 2002-07-18

Family

ID=7648253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007864 WO2002004516A2 (de) 2000-07-10 2001-07-09 Verwendungen des hitzeschockproteins gp96

Country Status (6)

Country Link
US (1) US20030175249A1 (de)
EP (1) EP1299113A2 (de)
AU (1) AU2001285814A1 (de)
CA (1) CA2415434A1 (de)
DE (1) DE10033245A1 (de)
WO (1) WO2002004516A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20070252A1 (it) * 2007-07-24 2009-01-25 Primiero Paolo Complessi di grp94 ed immunoglobuline g umane
WO2018049130A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
WO2000019828A1 (en) * 1998-10-05 2000-04-13 University Of Connecticut Health Center METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS $i(IN VITRO)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
WO2000019828A1 (en) * 1998-10-05 2000-04-13 University Of Connecticut Health Center METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS $i(IN VITRO)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SINGH-JASUJA HARPREET ET AL: "Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 11, 5 June 2000 (2000-06-05), pages 1965 - 1974, XP002198240, ISSN: 0022-1007 *
SINGH-JASUJA HARPREET ET AL: "The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 30, no. 8, August 2000 (2000-08-01), pages 2211 - 2215, XP002174948, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
CA2415434A1 (en) 2002-01-17
AU2001285814A1 (en) 2002-01-21
DE10033245A1 (de) 2002-01-24
EP1299113A2 (de) 2003-04-09
WO2002004516A2 (de) 2002-01-17
US20030175249A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2001034801A3 (en) Recombinant gelatin in vaccines
EP2246067A3 (de) Verfahren zur Auslösung, Verstärkung und Aufrechterhaltung von Immunreaktionen gegen eingeschränkte Klasse-I-MHC-epitope für prophylaktische oder therapeutische Zwecke
WO2002012341A3 (en) Her-2/neu fusion proteins
IL144371A0 (en) Her-2/neu fusion proteins
CA2259140A1 (en) Method of activating dendritic cells
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE389397T1 (de) Adjuvante zusammensetzungen
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002024739A3 (en) Spas-1 cancer antigen
WO2006081576A3 (en) Immunologically active compositions
WO2001040469A3 (en) Tick antigens and compositions and methods comprising them
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
WO2005026192A3 (en) Hpv cd8+ t-cell epitopes
WO2002004516A3 (de) Verwendungen des hitzeschockproteins gp96
WO2000061766A3 (en) Telomerase-specific cancer vaccine
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
WO2003093298A3 (en) Immunogenic peptides
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
EP2270171A3 (de) Haemophilus influenzae-Antigene und entsprechende DNA-Fragmente

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10338115

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2415434

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001285814

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001965092

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001965092

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001965092

Country of ref document: EP